4.7 Review

The role of α-synuclein in neurodegenerative diseases

期刊

PHARMACOLOGY & THERAPEUTICS
卷 105, 期 3, 页码 311-331

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2004.10.010

关键词

Parkinson's disease; LBD; synucleopathy; Lewy bodies; serine phosphorylation; protein aggregation; tissue transglutaminase; oxidative stress; nitration; protofibrils; fibrillation; dopamine transporter; tyrosine hydroxylase; iron; muscarinic receptors; endocytosis; vesicle recycling

向作者/读者索取更多资源

Alpha-synuclein is a 140 amino acid neuronal protein that has been associated with several neurodegenerative diseases. A point mutation in the gene coding for the alpha-synuclein protein was the first discovery linking this protein to a rare familial form of Parkinson's disease (PD). Subsequently, other mutations in the alpha-synuclein gene have been identified in familial PD. The aggregated protemaceous inclusions called Lewy bodies found in PD and cortical Lewy body dementia (LBD) were discovered to be predominantly alpha-synuclein. Aberrant aggregation of alpha-synuclein has been detected in an increasing number of neurodegenerative diseases, collectively known as symicleopathies. Alpha-synuclein exists physiologically in both soluble and membrane-bound states, in unstructured and alpha-helical conformations, respectively. The physiological function of a-synuclein appears to require its translocation between these subcellular compartments and interconversion between the 2 conformations. Abnormal processing of alpha-synuclein is predicted to lead to pathological changes in its binding properties and function. In this review, genetic and environmental risk factors for alpha-synuclein pathology are described. Various mechanisms for in vitro and in vivo alpha-synuclein aggregation and neurotoxicity are summarized, and their relevance to neuropathology is explored. (c) 2004 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据